Top

07-02-2015 | Hematologic cancers | Book chapter | Article

Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies

Authors: Tarec Christoffer El-Galaly, Martin Hutchings

Publisher: Springer International Publishing

Abstract

Optimal lymphoma management requires accurate pretreatment staging and reliable assessment of response, both during and after therapy. Positron emission tomography with computerized tomography (PET/CT) combines functional and anatomical imaging and provides the most sensitive and accurate methods for lymphoma imaging. New guidelines for lymphoma imaging and recently revised criteria for lymphoma staging and response assessment recommend PET/CT staging, treatment monitoring, and response evaluation in all FDG-avid lymphomas, while CT remains the method of choice for non-FDG-avid histologies. Since interim PET imaging has high prognostic value in lymphoma, a number of trials investigate PET-based, response-adapted therapy for non-Hodgkin lymphomas (NHL). PET response is the main determinant of response according to the new response criteria, but PET/CT has little or no role in routine surveillance imaging, the value which is itself questionable. This review presents from a clinical point of view the evidence for the use of imaging and primarily PET/CT in NHL before, during, and after therapy. The reader is given an overview of the current PET-based interventional NHL trials and an insight into possible future developments in the field, including new PET tracers.

Flowers CR, Armitage JO (2010) A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 10(6):414–423PubMed

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32(27):3048–3058PubMed

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol 32(27):3059–3068PubMed

Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M (2014) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(suppl 3):iii76–82PubMed

Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, Andre M et al (2012) Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(suppl 7):vii78–vii82PubMed

A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 1993; 329(14):987-994

Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479PubMed

Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258–1265PubMed

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558–565PubMed

10.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861PubMed

11.

Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31(11):1860–1861PubMed

12.

Kwee TC, Kwee RM, Nievelstein RA (2008) Imaging in staging of malignant lymphoma: a systematic review. Blood 111(2):504–516PubMed

13.

Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I et al (2010) 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51(1):25–30PubMed

14.

Le Dortz L, de Guibert S, Bayat S, Devillers A, Houot R, Rolland Y et al (2010) Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37(12):2307–2314PubMed

15.

Janikova A, Bolcak K, Pavlik T, Mayer J, Kral Z (2008) Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma 8(5):287–293PubMed

16.

Scott AM, Gunawardana DH, Wong J, Kirkwood I, Hicks RJ, Ho SI et al (2009) Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 36(3):347–353PubMed

17.

Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F et al (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24(8):2108–2112PubMed

18.

Wirth A, Foo M, Seymour JF, MacManus MP, Hicks RJ (2008) Impact of [¹⁸F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71(1):213–219PubMed

19.

Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG et al (2009) FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun 30(10):770–778PubMed

20.

Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L et al (2007) Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 79(3):205–209PubMed

21.

Falchi LK (2014) Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 123(18):2783–2790PubMed

22.

Papajik T, Myslivecek M, Urbanova R, Buriankova E, Kapitanova Z, Prochazka V et al (2013) 2-[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. Leuk Lymphoma 55(2):314–319PubMed

23.

Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S et al (2006) Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17(1):117–122PubMed

24.

Elstrom RL, Leonard JP, Coleman M, Brown RK (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19(10):1770–1773PubMedCentralPubMed

25.

Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G et al (2008) Role of whole-body [¹⁸F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med 113(4):578–590PubMed

26.

Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T et al (2013) PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 122(1):61–67PubMed

27.

Paone G, Itti E, Haioun C, Gaulard P, Dupuis J, Lin C et al (2009) Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging 36(5):745–750PubMed

28.

Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol 18(1):149–157PubMed

29.

Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS et al (2012) Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 91(5):697–703PubMedCentralPubMed

30.

Gallicchio R, Mansueto G, Simeon V, Nardelli A, Guariglia R, Capacchione D et al (2014) F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol 92(5):382–389PubMed

31.

Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U (2013) Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging 3(3):272–281PubMedCentralPubMed

32.

Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH et al (2013) Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer 119(6):1195–1202PubMed

33.

Carrillo-Cruz E, Marin-Oyaga VA, Rodriguez M, Borrego-Dorado I, de la Cruz Vicente F, Cantero EQ et al (2014) Role of 18F-FDG-PET/CT in the management of burkitt lymphoma. Eur J Haematol

34.

Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T et al (2007) FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18(10):1685–1690PubMed

35.

Casulo C, Schoder H, Feeney J, Lim R, Maragulia J, Zelenetz AD et al (2013) 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma 54(10):2163–2167PubMedCentralPubMed

36.

Moon SH, Cho SK, Kim WS, Kim SJ, Chan Ahn Y, Choe YS et al (2003) The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/t-cell lymphoma: a comparison with conventional staging methods. J Nucl Med 54(7):1039–1044

37.

Rankin SC (2003) Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 30(1):S56–S64PubMed

38.

Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S et al (1986) Chemotherapy for diffuse large-cell lymphoma–rapidly responding patients have more durable remissions. J Clin Oncol 4(2):160–164PubMed

39.

Gupta RK, Gospodarowicz MK, Lister TA (1999) Clinical evaluation and staging. In: Mauch P, Armitage JO, Diehl V, Hoppe R, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams and Wilkins, Philadelphia, pp 223–240

40.

Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P et al (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85(6):613–618PubMed

41.

Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma-comparison with CT. Leuk Lymphoma 39(5–6):543–553PubMed

42.

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T et al (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13(9):1356–1363PubMed

43.

Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ et al (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 34(10):1706–1710PubMed

44.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43(8):1018–1027PubMed

45.

Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H et al (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 31(1):22–28PubMed

46.

Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16(9):1514–1523PubMed

47.

Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106(4):1376–1381PubMed

48.

Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T et al (2006) FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107(11):2678–2687PubMed

49.

Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS (2009) High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol 20(2):309–318PubMedCentralPubMed

50.

Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK et al (2007) Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 48(8):1548–1555PubMed

51.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL (2011) 18F-FDG PET/CT for early response assessment in diffuse large b-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52(3):386–392PubMedCentralPubMed

52.

Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS et al (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28(11):1896–1903PubMedCentralPubMed

53.

Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A et al (2009) Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50(4):527–533PubMed

54.

Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C et al (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118(1):37–43PubMed

55.

Fludeoxyglucose F 18 positron emission tomography in predicting risk of relapse in patients with non-Hodgkin’s lymphoma who are undergoing combination chemotherapy with or without autologous stem cell or bone marrow transplant. http://www.clinicaltrials.gov/ct2/show/NCT00238368 Accessed Dec 17 2014

56.

Therapy for patients with untreated age-adjusted international prognostic index low-intermediate risk, high-intermediate risk, or high risk diffuse large B cell lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT00712582 Accessed Dec 17 2014

57.

Positron emission tomography guided therapy of aggressive non-Hodgkin’s lymphomas (PETAL). http://www.clinicaltrials.gov/ct2/show/NCT00554164 Accessed Dec 17 2014

58.

Tailoring treatment for B cell non-Hodgkin’s lymphoma based on pet scan results mid treatment. http://www.clinicaltrials.gov/ct2/show/NCT00324467 Accessed Dec 17 2014

59.

FDG-PET-stratified R-DICEP and R-beam/ASCT for diffuse large B-cell lymphoma (PET chop). http://www.clinicaltrials.gov/ct2/show/NCT00530179 Accessed Dec 17 2014

60.

A study of two associations of rituximab and chemotherapy, with a PET-driven strategy, in lymphoma (LNH2007-3B). http://www.clinicaltrials.gov/ct2/show/NCT00498043 Accessed Dec 17 2014

61.

Study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18f-fdg pet compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non Hodgkin’s lymphoma CD 20+. http://www.clinicaltrials.gov/ct2/show/NCT01285765 Accessed Dec 17 2014

62.

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 17(4):1244PubMed

63.

Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91(4):522–529PubMed

64.

Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A et al (2011) Positron emission tomography–computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29(23):3194–3200PubMed

65.

Zinzani PL, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V et al (2007) Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 7(4):291–295PubMed

66.

Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T et al (2014) PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging 41(3):408–415PubMed

67.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586PubMed

68.

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25(5):571–578PubMed

69.

Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J et al (2007) Aggressive and indolent non-Hodgkin’s lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 48(8):1522–1530PubMed

70.

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AsJM, Vitolo U et al (2014) [18F]Fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the international extranodal lymphoma study group IELSG-26 study. J Clin Oncol 32(17):1769–1775PubMed

71.

International extranodal lymphoma study group (IELSG): a randomized, open-label two-arm phase iii comparative study assessing the role of involved mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma. http://clinicaltrials.gov/ct2/show/NCT01599559 Accessed Dec 17 2014

72.

Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD et al (2013) Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol 31(S1):137 1-6-2013

73.

Hamlin PAZ (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102(6):1989–1996PubMed

74.

Weeks JC, Yeap BY, Canellos GP, Shipp MA (1991) Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9(7):1196–1203PubMed

75.

Guppy AE, Tebbutt NC, Norman A, Cunningham D (2003) The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 44(1):123–125PubMed

76.

Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD (2006) Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 17(6):909–913PubMed

77.

Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH et al (2012) Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol 91(11):1741–1745PubMed

78.

El Galaly TC, Mylam KJ, Boegsted M, Brown P, Rossing M, Gang AO et al (2014) Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 89(6):575–580PubMed

79.

El Galaly T, Prakash V, Christiansen I, Madsen J, Johansen P, Boegsted M et al (2011) Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma 52(4):597–603PubMed

80.

Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P et al (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27(11):1781–1787PubMed

81.

Cheah CY, Hofman MS, Dickinson M, Wirth A, Westerman D, Harrison SJ et al (2013) Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109(2):312–317PubMedCentralPubMed

82.

Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC et al (2011) High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma, 1–4

83.

Cheah C, Dickinson M, Hofman M, George A, Ritchie D, Prince HM et al (2014) Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. Ann Hematol 93(7):1193–1200PubMed

84.

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM et al (2013) Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol 88(5):400–405PubMed

85.

Picardi M, Pugliese N, Cirillo M, Zeppa P, Cozzolino I, Ciancia G et al (2014) Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission—randomized trial of routine surveillance imaging procedures. Radiology 272(1):262–274PubMed

86.

Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol–a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18(16):3025–3030PubMed

87.

Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP et al (1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens–a southwest oncology group trial. J Clin Oncol 16(1):48–55PubMed

88.

Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G et al (2002) Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 16(2):260–267PubMed

89.

Terasawa T, Dahabreh IJ, Nihashi T (2010) Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 15(7):750–759PubMedCentralPubMed

90.

Dickinson M, Hoyt R, Roberts AW, Grigg A, Seymour JF, Prince HM et al (2010) Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 150(1):39–45PubMed

91.

Cremerius U, Fabry U, Wildberger JE, Zimny M, Reinartz P, Nowak B et al (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant 30(2):103–111PubMed

92.

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102(1):53–59PubMed

93.

Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME et al (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124(2):608–613PubMed

94.

Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119(7):1665–1670PubMedCentralPubMed

95.

Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G et al (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44(9):1426–1431PubMed

96.

Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C et al (2001) Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 12(5):719–722PubMed

97.

Martiat P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C et al (1988) In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin’s lymphoma using positron emission tomography. J Nucl Med 29(10):1633–1637PubMed

98.

Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM et al (1998) Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39(10):1757–1762PubMed

99.

Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4(11):1334–1336PubMed

100.

Buchmann I, Neumaier B, Schreckenberger M, Reske S (2004) [18F]3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations–a pilot study. Cancer Biother Radiopharm 19(4):436–442PubMed

101.

Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H et al (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66(22):11055–11061PubMed

102.

Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M et al (2007) Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 48(4):746–753PubMed

103.

Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D et al (2007) Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging 34(11):1775–1782PubMed

104.

Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N et al (2011) A pilot study to evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med 52(12):1898–1902PubMed

105.

Herrmann K, Buck AK, Schuster T, Junger A, Wieder H, Graf N et al (2011) Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med 52(5):690–696PubMed

106.

Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ et al (2008) Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 10(6):349–355PubMed

107.

Hoffman RM (1984) Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 738(1–2):49–87PubMed

108.

Stern PH, Wallace CD, Hoffman RM (1984) Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 119(1):29–34PubMed

109.

Wheatley DN (1982) On the problem of linear incorporation of amino acids into cell protein. Experientia 38(7):818–820PubMed

110.

Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H (1991) Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med 32(6):1211–1218PubMed

111.

Nuutinen J, Leskinen S, Lindholm P, Soderstrom KO, Nagren K, Huhtala S et al (1998) Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur J Nucl Med 25(7):729–735PubMed

112.

Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y (2011) Comparison of 11C-Methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma. Mol Imaging Biol 13(6):1284–1289PubMed

113.

Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J et al (2009) Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 50(9):1500–1508PubMedCentralPubMed

114.

van Ufford HMEQ, Kwee TC, Beek FJ, van Leeuwen MS, Takahara T, Fijnheer R et al (2011) Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. Am J Roentgenol 196(3):662–669

Medicine Matters Oncology

Abstract